Rasburicase (Elitek)

Rasburicase is a recombinant fungal enzyme given by short IV infusion to rapidly break down uric acid in cancer patients at risk of tumor lysis syndrome — a genuine oncologic emergency in which chemotherapy destroys large numbers of tumor cells at once, flooding the bloodstream with their breakdown products. Approved by the FDA for children in 2002 and adults in 2009, it clears uric acid within hours by restoring an enzyme humans lost through evolution — but the same oxidizing chemical reaction that does this can trigger severe, sometimes fatal hemolytic anemia and methemoglobinemia in patients with an undiagnosed underlying enzyme deficiency, a risk serious enough that the drug carries a boxed warning and is contraindicated in that population. Its story since approval has also become a case study in a large gap between a drug's original FDA-labeled dosing and how it is actually used in many hospitals today.

Tumor lysis syndrome, and an enzyme humans lost through evolution

Tumor lysis syndrome is a genuine oncologic emergency: when chemotherapy kills a very large number of cancer cells at once — most often in bulky or highly chemo-sensitive blood cancers such as Burkitt lymphoma or acute leukemia — those dying cells release potassium, phosphate and nucleic acids into the bloodstream faster than the kidneys can clear them. The nucleic acids break down into uric acid, which can crystallize in the kidneys and trigger acute kidney injury, dangerous heart-rhythm disturbances from the potassium surge, and in severe cases, death. This site's pegloticase page describes how humans and other great apes lost a functional copy of the uricase (urate oxidase) gene during evolution — the enzyme most other mammals use to break uric acid down into a far more soluble compound, allantoin. Rasburicase restores that missing function using a genuinely different source and use case than pegloticase: rather than a PEGylated mammalian uricase engineered for months of repeated chronic dosing in gout, rasburicase is a recombinant fungal enzyme, cloned from Aspergillus flavus and produced in genetically engineered Saccharomyces cerevisiae (baker's yeast), given as a short IV course over a handful of days to resolve an acute emergency rather than manage a chronic condition.

The trials that won approval — children first, adults seven years later

The pivotal evidence for the original 2002 pediatric approval was an open-label, single-arm trial of 131 children, adolescents and young adults with newly diagnosed leukemia or lymphoma at risk of hyperuricemia from a high tumor burden, treated with rasburicase 0.15 or 0.2 mg/kg daily for 5 to 7 days. Among the 65 patients who presented with hyperuricemia, mean plasma uric acid fell from 9.7 mg/dL to 1.0 mg/dL within 4 hours of the first dose, and no patient in the trial required dialysis (Pui CH, Mahmoud HH, Wiley JM, Woods GM, Leverger G, Camitta B, Hastings C, Blaney SM, Relling MV, Reaman GH, "Recombinant Urate Oxidase for the Prophylaxis or Treatment of Hyperuricemia in Patients With Leukemia or Lymphoma," J Clin Oncol 2001;19(3):697-704, PMID 11157020, DOI: 10.1200/JCO.2001.19.3.697).¹ A separate, smaller randomized trial published the same year directly compared rasburicase against allopurinol, the standard oral urate-lowering drug, in 52 pediatric patients at high risk for tumor lysis: 4 hours after the first dose, rasburicase-treated patients had an 86% mean reduction in plasma uric acid versus 12% on allopurinol (P<.0001). The FDA approved rasburicase for pediatric patients on 17 July 2002 under the brand name Elitek.

An adult indication did not follow until more than seven years later. The supporting evidence was a multicenter, open-label, randomized Phase 3 trial enrolling 280 adults (275 evaluable) with hematologic malignancies at risk of tumor lysis syndrome, randomized to rasburicase alone for 5 days, rasburicase for 3 days followed by oral allopurinol for 2 days, or allopurinol alone for 5 days. The plasma uric acid response rate — the proportion of patients with uric acid at or below 7.5 mg/dL from day 3 through day 7 — was 87% on rasburicase alone, 78% on the rasburicase-then-allopurinol sequence, and 66% on allopurinol alone (Cortes J, Moore JO, Maziarz RT, Wetzler M, Craig M, Matous J, Luger S, Dey BR, Schiller GJ, Pham D, Abboud CN, Krishnamurthy M, Brown A, Laadem A, Seiter K, "Control of Plasma Uric Acid in Adults at Risk for Tumor Lysis Syndrome: Efficacy and Safety of Rasburicase Alone and Rasburicase Followed by Allopurinol Compared With Allopurinol Alone — Results of a Multicenter Phase III Study," J Clin Oncol 2010;28(27):4207-4213, PMID 20713865, DOI: 10.1200/JCO.2009.26.8896).² The FDA approved the adult indication on 16 October 2009, based on this trial's results, with the full peer-reviewed publication following in 2010.

A boxed warning: the same reaction that clears uric acid can break down red blood cells

The FDA-approved label for rasburicase carries three separate boxed warnings — anaphylaxis, hemolysis, and methemoglobinemia — each reported in fewer than 1% of the 887 patients pooled across its clinical trials, but serious enough individually to warrant top-of-label placement. Anaphylaxis is a general hypersensitivity risk that can appear with any infused foreign protein, including on a patient's first dose, and is not specific to any patient subgroup. The other two warnings are mechanistically linked and specific to a particular genetic subgroup, described below.

This G6PD-linked risk is a genuinely different kind of problem than the immunogenicity issues described on this site's pegloticase page: it is not about the drug losing effectiveness or triggering a reaction over repeated doses, but about a single dose causing serious harm in a specific, identifiable genetic subgroup — the reason pretreatment screening, not just post-dose monitoring, is built into how the drug is meant to be used.

Current status: a cost-driven shift toward lower off-label doses

Rasburicase remains FDA-approved and currently marketed by Sanofi as Elitek in the US (and as Fasturtec in Europe and other markets outside the US); no FDA-approved generic or biosimilar rasburicase product exists in the US. Since the original weight-based, up-to-5-day dosing regimen was approved, a substantial body of later research — including randomized comparisons of single-dose versus multi-day regimens and multi-site cost-utilization studies at oncology networks — has found that a single, much lower fixed dose (commonly 3 to 6 mg per adult, rather than a full weight-based multi-day course) achieves comparable plasma-uric-acid control in the large majority of patients, at a small fraction of the drug cost of the original labeled regimen, with a repeat dose given only if uric acid does not adequately fall. That evidence has not led to a formal FDA label change, but it has visibly shifted real-world practice: many US hospitals and community oncology networks now use a fixed low dose as their standard local protocol rather than the FDA-labeled weight-based regimen, a genuine gap between what the label says and how the drug is actually used in a large share of the patients who receive it today.